Northern Capital Management LLC Has $937,000 Position in Alexion Pharmaceuticals, Inc. (ALXN)

Northern Capital Management LLC cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 20.3% in the third quarter, HoldingsChannel.com reports. The firm owned 6,740 shares of the biopharmaceutical company’s stock after selling 1,720 shares during the quarter. Northern Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $937,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Atria Investments LLC boosted its holdings in Alexion Pharmaceuticals by 21.7% during the second quarter. Atria Investments LLC now owns 2,732 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 488 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH purchased a new stake in Alexion Pharmaceuticals during the second quarter worth $1,282,000. World Asset Management Inc boosted its holdings in Alexion Pharmaceuticals by 3.4% during the second quarter. World Asset Management Inc now owns 14,735 shares of the biopharmaceutical company’s stock worth $1,829,000 after buying an additional 487 shares in the last quarter. Amalgamated Bank boosted its holdings in Alexion Pharmaceuticals by 6.0% during the second quarter. Amalgamated Bank now owns 32,533 shares of the biopharmaceutical company’s stock worth $4,039,000 after buying an additional 1,852 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Alexion Pharmaceuticals by 16.7% during the second quarter. Nisa Investment Advisors LLC now owns 41,065 shares of the biopharmaceutical company’s stock worth $5,098,000 after buying an additional 5,870 shares in the last quarter. 93.64% of the stock is owned by institutional investors and hedge funds.

A number of analysts recently issued reports on ALXN shares. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. Stifel Nicolaus increased their price target on shares of Alexion Pharmaceuticals from $130.00 to $136.00 and gave the stock a “hold” rating in a report on Tuesday, September 25th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 5th. Citigroup increased their price target on shares of Alexion Pharmaceuticals from $173.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, September 25th. Finally, ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $161.50.

NASDAQ:ALXN opened at $118.62 on Friday. The company has a quick ratio of 2.74, a current ratio of 3.16 and a debt-to-equity ratio of 0.32. The firm has a market cap of $25.90 billion, a price-to-earnings ratio of 22.99, a P/E/G ratio of 1.00 and a beta of 0.99. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.28. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 earnings per share. As a group, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2018/11/17/northern-capital-management-llc-has-937000-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply